Teva Denied Protection from Generic!!!

Beef up the résumé, here comes the hammer! We are through.

 

Denied protection? Wear a rubber!

 

Serious question here. If generics can hit May 24th and the ruling could come as late as June 2015 (original expiration date September 2015), how can that be fair? That is 13 months of generic intrusion. How will manage care be managed? Certainly we can sue for irreparable harm.?

 

Only if Teva wins the case, right? And if Mylan prices high then Teva has less to collect on. Looks like our conversion over to 40 mg is going way faster than expected which makes me wonder how long they need 2 reps per territory anyway.

 

The fact that we are doing so well is a very good thing. They will keep us - all of us. How would the conversion go if they had the wrong or to small of a force?

 

Things would go just fine. You don't sell anything you moron. You lie about sales calls, drive around in your company vehicle and live in a dream world. We have had it very good in the industry for a long time. The party is over or about over. Now companies are branding themselves as having specialty drugs. Whatever! Generics are here and science is hitting a wall.

 

I have a great idea. Lets sue the US government.

 

Isn't it ironic:
The FTC accuses Cephalon of paying four drug companies—one of which was Teva—more than $200 million to delay generic versions of Provigil until 2012. Cephalon is contesting the FTC’s accusations.

In a January 2014 hearing in the US District Court for the Eastern District of Pennsylvania, the FTC suggested an overall settlement figure of approximately $6.8 billion to compensate consumers and other purchasers in the case. The FTC also wants the court to block Cephalon from entering into future pay-for-delay deals for some period of time.

The next step is a possible jury trial.

 

Teva faces “irreparable harm” if the court doesn’t block Copaxone’s generic competitors, according to the complaint. The drugmaker “stands to lose hundreds of millions of dollars within months of the FDA approving” the generic products, the company said.

 

Teva’s lawsuit, accusing the Food and Drug Administration of improperly dismissing its calls for more testing of generic forms of Copaxone before they go on the U.S. market, was thrown out yesterday by a federal judge in Washington. Copaxone, the company’s bestselling drug, contributes more than 50 percent of earnings, according to analysts.

Tick tock.....tick tock.....tick tock....

 

Teva’s suit against FDA was simply a desperate, last-minute tactic,” Heather Bresch, chief executive officer of Canonsburg, Pennsylvania-based Mylan, said today in a statement. “We continue to see no barrier to FDA approval of Mylan’s generic Copaxone following patent expiry

tick tock....tick tock...tick tock....

 

505b2 filing and estriol, this should be the next course of action for Teva. It puts the generics on hold. Teva should be able to get the rights from synthetic biologics for dirt cheap, they're idiots if they don't at least try it. How many times in the history of the world have legal loopholes been used as a stalling tactic? Especially a stalling tactic that brings in a billion per quarter?

 

In a previous forecast, Teva stated that net sales in 2014 would come in between $19.8 billion to $20.8 billion if Copaxone maintained market exclusivity, but if sales could fall to $19.3 billion to $20.3 billion if it faces generic competition.The outlook for Teva's bottom line is similar -- it expects full-year operating profits between $5.35 billion to $5.65 billion if Copaxone remains protected, and profits of $4.8 billion to $5.1 billion if generics hit the market.

 

Those numbers are absurd. If patients can get the generic at fractional cost, why would they buy the brand name? There's no way Teva will maintain those numbers. I'm already seeing Copax users on MS forums talking about the best places online to order oral estriol & generic GA to get the added benefits (Natco & Taj have great prices on their sites). As word spreads, more cash strapped patients will switch to generic in a heartbeat.

 

You losers are known for launching generics before patents have expired. How's it feel? hahahahahahahahahaha

 

? I read that we had 30 month stay before generics could enter the market.

 

But as competition to the original looms, will Teva consider discontinuing off-patent Copaxone to push patients toward the protected version in a quest to maintain market share? The short answer: Yes, but not just yet.

Have fun maintaining rapport playing hard ball. I hope your customers reward you with what you deserve if this is rolled out.

 

I smell an ex Teva rep who went to Genzyme. Are you upset you made a bad move and now are wishing Teva bad luck? How low was your bonus?

 

You are all idiots....your view of what is really happening in pitifully ignorant, but that's just because you don't really understand the game.

 

That's on the 40 mg. 20 mg patent is gone!